What is William Blair’s Estimate for APLS Q1 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at William Blair issued their Q1 2025 EPS estimates for Apellis Pharmaceuticals in a research report issued on Monday, October 28th. William Blair analyst L. Hanbury-Brown forecasts that the company will post earnings per share of ($0.09) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS and Q3 2025 earnings at $0.13 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. During the same period last year, the business earned ($1.02) earnings per share. The firm’s revenue was up 110.2% on a year-over-year basis.

Several other brokerages also recently issued reports on APLS. Wedbush raised their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Robert W. Baird cut their price target on Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a report on Monday, September 23rd. Mizuho cut their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. The Goldman Sachs Group raised their price target on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Scotiabank started coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $35.00 price target for the company. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $65.41.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $27.26 on Thursday. Apellis Pharmaceuticals has a 1-year low of $26.28 and a 1-year high of $73.80. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The firm has a fifty day simple moving average of $32.52 and a 200 day simple moving average of $37.94. The stock has a market capitalization of $3.31 billion, a PE ratio of -7.88 and a beta of 0.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals in the first quarter valued at about $89,000. nVerses Capital LLC grew its holdings in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Apellis Pharmaceuticals by 1,300.8% during the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after purchasing an additional 3,330 shares during the period. CWM LLC raised its position in shares of Apellis Pharmaceuticals by 299.9% during the second quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after purchasing an additional 3,113 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the period. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).